The US digital health sector is rapidly reshaping how healthcare is delivered.
Companies are leveraging technology to make healthcare more personalised and accessible.
From virtual consultations to artificial intelligence (AI) powered diagnostics, it is clear that the market is gearing towards efficiency.
Here are three high-growth digital health leaders that investors should keep an eye on.
DexCom is a medical device manufacturer focusing on continuous glucose monitoring systems (CGM) for diabetics.
One of their flagship products is Stelo, a non-invasive wearable biosensor which tracks the blood-glucose level of the user in real-time and updates the user with the information on their smartphones.
In the second quarter of 2025 ending 30 June 2025 (2Q 2025), DexCom reported an increase in revenue of 15% year-on-year (YoY) to US$1.2 billion.
The firm also saw a rise in net profits of 25.3% YoY to US$179.8 million.
This growth can be attributed to the successful expansion into new markets which is supported by the climb in international revenue by 16% YoY to US$316.1 million.
The strong financial performance was driven by the increased accessibility and improvements in the features of Stelo.
In this quarter, Stelo was listed on Amazon (NASDAQ: AMZN), which greatly expanded its distribution channels.
There were also developments that improved the quality of Stelo such as the integration of generative AI into the product, helping to provide increased personalisation.
DexCom also partnered with Oura, a smart ring manufacturer.
This partnership enabled the sharing of data between both firms, thereby allowing for convenient glucose tracking and meal logging on Oura’s rings.
This integration of DexCom’s technology in Oura’s products not only gives the brand more exposure, but also helps it to tap into the wellness market.
Doximity is a cloud-based professional network for US physicians that helps to streamline clinical workflows using automation and telehealth tools.
In the fourth quarter of its fiscal year 2025 ending 31 March 2025 (4Q FY2025), Doximity reported revenue growth of 17% YoY to US$138.3 million.
The firm’s net profit also soared by 53.9% YoY to US$62.5 million.
One of the key drivers for this growth is the rise in the usage of the platform’s workflow tools to over 620,000 unique active providers.
Another driver would be the climb in subscription revenue of 17% YoY to US$131.9 million, combined with a 119% net revenue retention rate.
In the 4Q FY2025 earning call, management highlighted the new features of Doximity GPT AI products.
The new features include the ability to track a patient’s lab results over time, summarise key clinical findings, and identify complex diagnostic signs.
The use of sophisticated AI products improves not only the accuracy of clinical work but also increases efficiency and reduces operational cost.
These benefits make Doximity’s cloud network highly appealing for medical professionals.
Hims & Hers or Hims is a telehealth platform that connects consumers to healthcare professionals for personalised treatment plans.
In 1Q 2025, Hims reported a revenue uptick of 111% YoY to US$586 million.
The firm also had a 344.7% YoY surge in net profits to US$49.5 million.
This robust financial showing can be attributed to a growing customer base along with higher monetisation per customer.
For 1Q 2025, the number of subscribers grew by 38% YoY to 2.4 million.
Moreover, the monthly online revenue per average customer soared by 53% YoY to US$84.
On 29 April 2025, Hims announced a long-term partnership with Novo Nordisk A/S (NYSE: NVO), a global manufacturer of innovative medicine for chronic illnesses.
The partnership involves the distribution of Novo Nordisk’s weight management drug, Wegovy, via Hims’ platform.
This product was priced as a bundled membership of US$599 per month.
The collaboration enables weight loss therapy to be more accessible while maintaining affordability.
Consequently, this agreement increases Hims’ appeal to customers and will boost the company’s topline growth.
On 3 June 2025, Hims announced a plan to acquire ZAVA, a UK-based digital health provider.
This deal will give Hims access to the UK and European markets with ZAVA’s 1.3 million active users.
Management expects the acquisition to be accretive to earnings by 2026.
As digital transformation becomes more prominent in the healthcare sector, these three companies are leading the pack with innovative products and services.
With a strong display of financial performance and innovation, these firms represent an investment opportunity worth considering.
As the healthcare industry continues to evolve, investors should pay attention to such digital health stocks that can help to lift the value of their portfolios.
Generative AI is reshaping the stock market, but not in the way most investors think. It’s not just about which companies are using AI. It’s about how they’re using it to unlock new revenue, dominate their markets, and quietly reshape the business world. Our latest FREE report “How GenAI is Reshaping the Stock Market” breaks the hype down, so you can invest with greater clarity and confidence. Click here to download your copy today.
Follow us on Facebook, Instagram and Telegram for the latest investing news and analyses!
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.